
LifeMD

Investor Presentation

March 2024 NASDAQ: LFMD

9:41	÷ 🗈
Life MD	≡
Schedule your appointment	
Masching Today -20 min wait Jan 23	
• 👰 Dr. Jennell Giles	
🔿 🗕 Any available provider	
🕂 Schedule an appointment	
Possible conditions:	
Middle ear infection Strong evidence	>
Inflamation of external ear	,



Important cautions regarding forward-looking statements

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this presentation may be identified by the use of words such as: "believe," "expect," "anticipate," "project," "should," "plan," "will," "may," "intend," "estimate," predict," "continue," and "potential," or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.


Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, "Risk Factors" identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

This presentation is not an offer to sell or a solicitation of an offer to purchase securities by the Company. Any such offer or solicitation, if any, will only be made by means of offering documents (e.g., prospectus, offering memorandum, subscription agreement and or similar documents) and only in jurisdictions where permitted by law. Certain information contained herein has been provided by or obtained from third-party sources and has not been independently audited or verified by the Company. The Company makes no representation or warranty, express or implied as to the accuracy or completeness of information contained in this document, and nothing contained in this document is, or shall be relied upon as, a promise or representation by the Company.

This presentation is not intended for any commercial purpose but strictly for educational or informational purposes only. Please note that some photographs and images appearing in this presentation are not necessarily those of the Company or accurate representations of its products or operations, but may be stock images, third-party operations, product mock-ups, and/or may have been edited for competitive or confidentiality reasons. Any third-party images not owned by the Company are used for non-commercial, illustrative, and educational 'fair use' purposes only. All images and trademarks are the property of their respective owners.

Building the leading platform for comprehensive virtual healthcare

- End-to-end, compliance-first platform for direct-toconsumer virtual primary care
- Early-mover advantage and partnership strategy create a deep competitive moat
- Affiliated 50-state medical group anchored by full-time providers who provide industry-leading, comprehensive virtual care
- Flexible and proprietary technology stack proven to support complex virtual care at scale
- 73% equity holder in WorkSimpli, a rapidly growing SaaS business in the document management space





0


M

Revenue Guidance for 2024

250+ Employees Across the US

Investment highlights

- Proven ability to operate at scale within large and growing addressable markets thanks to robust infrastructure
- Differentiated, end-to-end technology platform and affiliated medical group supporting complex virtual primary care needs of 800-1,000 new patients per day
- Significant growth opportunities from joint ventures, strategic partnerships, and licensing transactions
- EBITDA positive with \$18-\$22M of Adj. EBITDA forecast for 2024 and balance sheet capitalized to pursue strategy
- High-margin products/services generating 85%+ consolidated gross margins
- WorkSimpli providing high-margin recurring revenue with potential for significant exit value



Telehealth can solve many of the biggest problems facing the U.S. healthcare system

	Need	Solution
Timeliness	1/3 of Americans don't have a primary care doctor, and the average wait time to see a family doctor is 20.6 days. ¹	At LifeMD, the median time from scheduling to the first provider appointment is only 2 hours.
Cost	Four in 10 U.S. adults say they have delayed or gone without medical care in the last year due to cost. ²	Patients in all 50 states can see a LifeMD-affiliated provider for as little as \$39/mo. via their PC or smartphone.
Access	Only 8% of Americans undergo routine, preventative screenings due mainly to issues with cost and access. ³	Routine, preventive care is built into LifeMD's virtual primary care membership programs.
Chronic Conditions	50% of the U.S. population has a chronic disease, and 86% of healthcare costs are attributable to chronic conditions. ⁴	LifeMD's comprehensive care platform, combined with lab and in-home device partners, supports the ongoing needs of patients with chronic conditions.

1. Merritt Hawkins, 2022 Survey of Physician Appointment Wait Times, 2022,

2. Gallup website, Record High in U.S. Put Off Medical Care Due to Cost in 2022, 2022


3. F. Batarseh, I. Ghassib, D. Chong, P. Su Preventive healthcare policies in the US: solutions for disease management using Big Data Analytics, 2020

4. H. Holman The Relation of the Chronic Disease Epidemic to the Health Care Crisis, 2020

5


A \$170 billion total addressable market in the U.S.

LifeMD's virtual care platform is addressing unmet needs in primary care and specialized healthcare.



Life MD

LifeMD has built an end-to-end platform for comprehensive virtual healthcare



Technology designed to provide Best-in-class experience and care for all stakeholders

Life MD	=	
Schedule your appointment		
Masap Today Today -20 min wait Jan 23 Today	Jan 24	
• 👰 Dr. Jennell Giles		
🔿 🧕 Any available pro	ovider	
🕂 Schedule an appoir	ntment	
Possible conditions:		
Middle ear infection Strong evidence	>	

For Patients

Patients benefit from an intuitive virtual care platform powered by a 50-state provider network, lab work partnerships, mail order pharmacy, and Al-powered tools.

For Providers

Streamlined workflow optimization with proprietary EHR and scheduling capabilities allow providers to focus on patient interactions that ensure the highest quality clinical care.

Evan Bates, 40

For Partners

Flexible partnerships with unique offerings are enabled by sophisticated de-identified data analytics, custom dashboards, and telehealth capabilities.

CE OPTAVIA

Welcome! We've designed a weight loss

214 lbs

program specifically for OPTAVIA® clients

Weigh

Getting starter



For Industry

Life sciences companies who partner gain access to robust direct-topatient capabilities across marketing, and medication adherence and compliance.



Our affiliated medical group, staffed by full-time providers, is central to our success

99% Of consults start on time*	850K Consults completed	200+ Different conditions LifeMD treats	4.9/5 Average physician rating
98% Patients satisfied with their care	50 State coverage	Dr. Gupta LifeMD Affiliated Provider "I love what I do because I get the pleasure of being a part of my patients' lives."	AlifeMD Paye Co.

*within 15 minutes for soonest available appointment during queue hours and within 2 minutes of scheduled appointment time slots

Our success is driven by three core pillars

DTC Telemedicine

- Subscription-based treatment
 + Rx Offerings
- Established, wholly-owned brands with large customer base
- Supported by mail order pharmacy capabilities
- E.D., pain, dermatology, insomnia, allergy & asthma


Virtual Primary Care

- Services include primary care, urgent care, and chronic condition management
- Supported by affiliated 50-state Medical Group
- Lab work powered by integrations with Quest, Labcorp, and GetLabs
- Weight Management/GLP-1 Program

B2B Solutions

- Digital front-door strategies for healthcare product companies
- Telehealth services for payors and employers
- Zero-cost patient flow for LifeMD platform
- Comprehensive devicesupported Cardiovascular Care Program

Our track record of strategic focus and growth



Clear strategy focused on scaling high-value revenue streams

Launch cardiova Launch commer	ale weight manageme ascular health and hor rcial health insurance are/Medicaid infrastru
-	ew patient growth in E -sell patients to men's
-	gic partnerships in GLI ild long-term partners companies

Virtual Primary Care


RexMD

Partnerships

nt/GLP-1 offering rmone therapy offerings programs in 10 states cture for 2024 deployment E.D. business s health primary care P-1 space

Key Priorities

ships with Life Sciences and





WorkSimpli Software is rapidly growing and highly profitable

- Rapidly growing, global provider of Workplace and document Software-as-a-Service offerings to consumers and small businesses specializing in the pdf, resume/ HR, digital signature and forms markets
- Over 158,000 subscribers with platform available in approximately 20 languages globally
- Full Year 2024 revenue forecast of **\$65 million, up 20% versus prior year**
- Highly profitable enterprise with Adjusted EBITDA margins exceeding 30% and Full Year 2024 Adjusted EBITDA forecast of \$18-\$20 million
- Scalable platform with capabilities to rapidly expand in adjacent verticals on existing platform and provide users one-stop pricing for and access to the full suite of platform offerings
- LifeMD maintains over 73% ownership in WorkSimpli with sizeable near-term cash flow back to LifeMD and potential for future significant exit value
- Separately led and managed by highly skilled and experienced management with a demonstrated track record in building related consumer technology businesses

Our management team has deep experience leading innovative healthcare organizations



Justin Schreiber Chief Executive Officer & Chairman JLS VENTURES



Marc Benathen Chief Financial Officer EOUINOX blink ANN TAYLOR



Stefan Galluppi Chief Innovation Officer



Jessica Friedeman Chief Marketing Officer

healthgrades BM Watson

1	-			
	(9)	6		
	1º	3	r	
1	P	1		

Eric Yecies General Counsel & Chief Compliance Officer

Holland & Knight GOODWIN



Dennis Wijnker Chief Technology Officer

dr. evidence CALYX



Nick Alvarez Chief Acquisition Officer

Internet Brands



Our Board of Directors

















John Strawn

Joseph DiTrolio, MD

Naveen Bhatia

Bertrand Velge

Roberto Simon

Bobby Jindal

Joan LaRovere, MD

William Febbo


lifemd

Our businesses have experienced rapid, consecutive YoY Growth

\$200M 2024E Revenue Forecast

31% Forecast 2024 Growth Rate Versus 2023

850K+ Patients & Customers To-Date




Telehealth

WorkSimpli

\$200M

Rapid growth in profitability after achieving adjusted EBITDA profit in Q4 '22

Annual consolidated adjusted EBITDA (\$ millions)




lifeMD

Rapidly expanding gross margins and increasing leverage on marketing spend driving continued growth in profitability

90% 89% 88% 87% 86% 85% 84% 83% 82% Q22022 Q32022 Q42022 Q12023 Q22023 Q32023 Q42023

Consolidated Gross Margin %




Marketing cost as % of net revenue includes Telehealth and WorkSimpli results.

2024 guidance reflects substantial increases in both revenue and profitability

	FY 2024 GUIDANCE	FY 2023 ACTUAL	DELTA		
Telehealth Revenue	\$135 million	\$98 million	+38%		
WorkSimpli Revenue	WorkSimpli Revenue \$65 million		+20%		
Consolidated Revenue	\$200 million	\$152 million	+31%		
Consolidated Adj. EBITDA \$20 million		\$12 million	+67%		

In summary

- Significant presence within established and growing addressable markets
- Proprietary technology platform differentiated by leading 50-state, affiliated physician network
- High margin products/services generating 85%+ consolidated gross margins
- Powerful telehealth infrastructure enabling highly scalable differentiated offerings
- Free cash flow breakeven with expanding adjusted EBITDA margins
- **Diversified, non-cyclical revenue streams** covering numerous healthcare areas



13:00 Prime 13:00 D	Tasks My Pa		1 Patient 1 Me		n Bates, 40 Management		Details © Cl	hart
+ Dashboard	● All ● 12 Patient ○	Appointments • 2 Post-consu	Category C	• Renewal 🙆 Me		Actions	V Mark comp	slete
Tasks				2nd renewal		Require appointment	Prescribe compound	
6				Prescription Wegovy		Sig 0.10 ml [0.25 mg + 50	0 mcg] weekly	
	-0			Qty 4 ml	Prescribed 7/13/2023	Renews 8/10/2023	Renewal 2nd	
	A			Weight -4 lbs Last renewal ~ 8% from start	: 245 lbs Current: 225 lb	Side effects		
								Summent
Evan Bates 02:34		* : *		Jul 10				25 lbs
	V <u>Is (1951</u>			All	Week	Month	Year	
	John Doe, 35	📑 9:30 am PDT in 6 min	Result	Patient messages	Staff notes			L
	John Doe, 35	Yesterday - 10:30 am PDT	Request					
v103	John Doe, 35	📑 Aug 12 - 10:30 am PDT	Appointment: Mis	Medical Support	t SMS		General health	~

Appendix

Reconciliation of GAAP Net Loss to Adjusted EBITDA (in whole numbers, unaudited)

	Fourth Quarter Ended December 31,			Year Ended December 31,			
		2023		2022	2023		2022
Net loss attributable to common shareholders	\$	(4,508,664)	\$	(12,711,912)	\$ (23,702,242)	\$	(48,641,909)
Interest expense (excluding amortization of debt discount)		522,241		728,856	1,755,656		820,946
Depreciation, amortization and accretion expense		1,959,468		1,340,626	6,767,447		4,044,056
Amortization of debt discount		100,444		-	333,939		-
Loss (gain) on debt extinguishment		-			325,198		(63,400)
Financing transactions expense		38,431		98,333	773,932		250,348
Litigation costs		168,600		168,162	1,594,930		1,685,521
Inventory and reserve adjustments		404,694		699,057	637,324		929,718
Deferred revenue adjustment		-		2,918,942			2,918,942
Severance costs		17,400		181,824	25,092		360,914
Acquisitions expenses		30,909		127,539	158,047		392,692
Change in fair value of contingent consideration		-		(2,614,000)	-		(5,101,000)
Goodwill and intangible asset impairment charges		-		6,127,596			8,862,596
Insurance acceptance readiness		252,250			318,884		-
Sarbanes Oxley readiness		151,248			199,824		-
Accrued interest on Series B Convertible Preferred Stock		-		114,685	506,991		455,000
Foreign exchange (gain) loss		368,793		393,147	1,165,412		1,078,389
Taxes		428,000		360,700	498,378		360,700
Dividends		1,399,560		812,562	5,371,450		3,250,250
Stock-based compensation expense		3,645,607		1,884,614	12,489,343		13,734,614
Net income attributable to noncontrolling interests		509,880		360,168	2,756,935		514,632
Adjusted EBITDA	\$	5,488,861	\$	990,899	\$ 11,976,540	\$	(14,146,991)

LifeMD

Company Contact

Marc Benathen marc@lifemd.com

Media Contact

press@lifemd.com

